Get started
Award

SRP84

Funded outputs count: 8
Funder award ID: SRP84
OpenAlex ID: G7780772506
T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy
2026 · Lauren van den Broecke, Arne Van der Vreken, et al. · Signal Transduction and Targeted Therapy · 2
Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma
2026 · Michiel De Coster, Lukas Hyka, et al. · Journal of Extracellular Vesicles
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
2026 · Chenggong Tu, Arne Van der Vreken, et al. · Experimental Hematology and Oncology · 2
PDF
Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors
2025 · Fien Meeus, Arne Van der Vreken, et al. · Molecular Therapy Oncology · 3
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
2025 · Arne Van der Vreken, Fien Meeus, et al. · Journal of Hematology & Oncology · 8
PDF
Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency
2025 · Chenggong Tu, Raphael Leblanc, et al. · HemaSphere · 3
PDF
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy
2025 · Arne Van der Vreken, Fabien Thery, et al. · Journal for ImmunoTherapy of Cancer · 9
Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties
2024 · Heleen Hanssens, Fien Meeus, et al. · International Journal of Molecular Sciences · 11
Year
Topic